Treats major depressive disorder (MDD). ANDA 210014, held by Yichang Humanwell Pharmaceutical. Desvenlafaxine Succinate.
As of Nov 22, 2026, ANDA 210014 (Desvenlafaxine Succinate), held by Yichang Humanwell Pharmaceutical, was first approved by FDA on Oct 1, 2018, with 4 approved supplements and 0 published complete response letters.
Desvenlafaxine is indicated for the treatment of adults with major depressive disorder (MDD).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 1, 2018 | Original application | Approved | None posted |
| Desvenlafaxine SuccinateEQ 50MG BASE · tablet, extended release;oral | Desvenlafaxine Succinate | Rx |
| Desvenlafaxine SuccinateEQ 100MG BASE · tablet, extended release;oral | Desvenlafaxine Succinate | Rx |
| Desvenlafaxine SuccinateEQ 25MG BASE · tablet, extended release;oral | Desvenlafaxine Succinate | Rx |
| Nov 1, 2023 | Supplement 17Labeling · Standard review | Approved | None posted |
| Feb 21, 2023 | Supplement 14Labeling · Standard review | Approved | None posted |
| Feb 21, 2023 | Supplement 12Labeling · Standard review | Approved | None posted |
| Feb 21, 2023 | Supplement 10Labeling · Standard review | Approved | None posted |
| Oct 1, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters